Chronic wounds represent one of healthcare’s most persistent and costly challenges, affecting millions of people worldwide and placing significant pressure on healthcare systems. For patients living with conditions such as diabetes, wounds that fail to heal can lead to severe infections, amputations, prolonged hospitalisation, and even death. Despite advances in medicine, treatment options remain limited, particularly as antimicrobial resistance continues to reduce the effectiveness of conventional therapies. Estonian medtech company Nanordica Medical is working to change that reality through a new approach that combines infection control with accelerated wound healing, and the company has now secured fresh funding to support its next stage of growth.
Nanordica Medical has raised €1.6 million in a financing round led by Estonian investment firm 2C Ventures. Existing investors including Specialist VC, Superangel, Amalfi, the Health Founders syndicate led by Erki Mölder, and the EstBAN syndicate led by Heidi Kakko and Martin Goroško also participated in the round.
The funding will help the company complete ongoing clinical studies, finalise regulatory approvals, and prepare for the commercial launch of its wound care technology across Europe.
Addressing a Global Healthcare Problem
Around 100 million people worldwide suffer from chronic wounds that do not heal properly.
More than half of these wounds become infected, creating serious health risks and increasing treatment complexity.
Among the most severe forms are diabetic foot ulcers, which remain one of the leading causes of infection and lower limb amputations among people with diabetes.
The scale of the problem is significant. Every 20 seconds, a person with diabetes loses a leg due to amputation.
Healthcare professionals often describe diabetic foot ulcers as a silent health crisis because their mortality rates and treatment costs are comparable to those associated with cancer.
Current treatment guidelines primarily recommend systemic antibiotics for infected wounds. However, these medications frequently struggle to reach wound sites in sufficient concentrations, while growing antimicrobial resistance is limiting their long term effectiveness.
Introducing Premotiv Technology
Nanordica Medical has developed a patented technology platform known as Premotiv to address these challenges.
Unlike many existing antibacterial wound dressings, Premotiv is designed to prevent infection while simultaneously supporting the natural wound healing process.
Historically, wound care products have faced a trade off between antimicrobial effectiveness and safety for healthy skin cells.
Products containing high concentrations of antibacterial agents can help control infections but may also damage surrounding tissue and slow healing.
Premotiv was developed to overcome this limitation by combining antimicrobial protection with skin cell compatibility, making it suitable for both infected wounds and wounds at risk of infection.
Promising Clinical Results
The company has already generated encouraging clinical evidence supporting its approach.
In a randomised controlled trial involving 30 patients with diabetic foot ulcers, the Premotiv dressing achieved a 43 per cent reduction in wound area after just one week of treatment.
By comparison, standard silver based dressings delivered a 13 per cent reduction during the same period.
The results were recently published in the Journal of Wound Care, providing important scientific validation for the technology.
Nanordica is now conducting a larger multicentre, double blind, randomised clinical trial involving patients with diabetic foot ulcers.
More than 120 patients have already been enrolled, making it one of the largest studies of its type.
The company expects the trial to provide additional clinical evidence supporting reimbursement decisions, treatment guideline inclusion, and broader adoption within healthcare systems.
Building Toward Commercial Launch
Nanordica has already demonstrated commercial potential through its veterinary wound care product, Ravimus Vet, which was launched in 2023.
The product is currently distributed across six countries and has received positive market acceptance.
The company is now preparing to introduce its human healthcare product following CE marking approval.
Its position has also been strengthened by the recent granting of a European patent, further protecting its intellectual property and supporting future product expansion.
Several of the company’s activities, including clinical development, have been supported by a €2.4 million European Innovation Council Accelerator grant.
Preparing for the Next Phase
The newly secured funding will allow Nanordica Medical to complete its large scale clinical study, strengthen the economic case for Premotiv, and finalise regulatory requirements for market entry.
As healthcare providers continue searching for alternatives to antibiotics and more effective solutions for chronic wound management, Nanordica is positioning itself as a company capable of addressing both infection control and healing outcomes simultaneously. By combining clinical evidence, patented technology, and a focus on reducing reliance on antibiotics, the company aims to improve care for millions of patients suffering from chronic wounds around the world.